Cancer Trials: Patient-Reported Outcomes Should Measure Five Core Concepts, US FDA Says
Heterogeneity in PRO assessment strategies has lessened the regulatory utility of such data from cancer trials, the agency says; new draft guidance recommends systematic assessment of a core set of PROs in registrational studies using fit-for-purpose tools and includes examples of acceptable instruments.
You may also be interested in...
Incorporation of the Ped-PRO-CTCAE instrument would help inform short-term tolerability and long-term effects of treatment, particularly newer immunotherapy agents, but there are logistical and operational challenges to overcome, advisory committee members said.
A new patient-reported outcomes instrument for assessing toxicities in oncology trials ultimately could create an opportunity for comparative tolerability claims across cancer treatments.
New trial designs would be needed to support labeling claim using National Cancer Institute's PRO-CTCAE instrument.